Cemiplimab removed from reimbursable drugs in France

Eur J Cancer. 2021 May:149:11-13. doi: 10.1016/j.ejca.2021.02.041. Epub 2021 Apr 1.

Authors

Félix Pham¹, Bénédicte Reynaud², Bertrand Favier³, Sophie Darnis⁴, Mona Amini-Adle²

Affiliations

¹ Service de Dermatologie, Centre Léon Bérard, Lyon, France. Electronic address: felix.pham@lyon.unicancer.fr.
² Service de Dermatologie, Centre Léon Bérard, Lyon, France.
³ Service de Pharmacologie, Centre Léon Bérard, Lyon, France.
⁴ Délégation à La Recherche Clinique et à l'innovation, Centre Léon Bérard, Lyon, France.

PMID: 33812142
DOI: 10.1016/j.ejca.2021.02.041

No abstract available

Publication types

Letter

MeSH terms

Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized / adverse effects
Antibodies, Monoclonal, Humanized / economics*
Antibodies, Monoclonal, Humanized / therapeutic use*
Antineoplastic Agents, Immunological / adverse effects
Antineoplastic Agents, Immunological / economics*
Antineoplastic Agents, Immunological / therapeutic use*
Carcinoma, Squamous Cell / drug therapy*
Carcinoma, Squamous Cell / economics*
Carcinoma, Squamous Cell / mortality
Carcinoma, Squamous Cell / secondary
Cost-Benefit Analysis
Drug Approval
Drug Costs*
Female
France
Humans
Insurance, Health, Reimbursement*
Insurance, Pharmaceutical Services / economics*
Male
Middle Aged
Progression-Free Survival
Skin Neoplasms / drug therapy*
Skin Neoplasms / economics*
Skin Neoplasms / mortality
Skin Neoplasms / pathology
Time Factors

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
cemiplimab